Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
m |
|||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' AG-221, CC-90007 | *'''Code names:''' AG-221, CC-90007 | ||
| + | *'''Generic name:''' enasidenib mesylate | ||
*'''Brand name:''' Idhifa | *'''Brand name:''' Idhifa | ||
==References== | ==References== | ||
Revision as of 16:29, 30 July 2020
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).[1]
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Also known as
- Code names: AG-221, CC-90007
- Generic name: enasidenib mesylate
- Brand name: Idhifa